Cardinal Health, Inc.'s Stock Analysis

Cardinal Health Annual Meeting Results and Shareholder Votes

Cardinal Health, Inc. held its 2025 Annual Meeting of Shareholders on November 5, 2025. During the meeting, shareholders elected 12 nominees to the Board of Directors, each serving until the 2026 Annual Meeting or until their successors are appointed. Additionally, shareholders approved a non-binding advisory vote on the compensation of the Company's named executive officers and ratified the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending June 30, 2026.

The results of the votes indicate shareholder support for the current leadership and compensation structure, which may influence investor confidence. The election of the board and the approval of the auditor are critical governance matters that can impact the company's operational direction and financial reporting, factors that may be relevant for investors monitoring Cardinal Health's performance.

Nov 06, 2025 16:13:37

Cardinal Health Reports 22% Revenue Growth in Q1 2026

Cardinal Health reported a revenue increase of 22% for the first quarter of fiscal year 2026, reaching $64 billion. GAAP operating earnings rose 18% to $668 million, while GAAP diluted earnings per share (EPS) increased 11% to $1.88. Non-GAAP operating earnings saw a 37% increase to $857 million, leading to a 36% rise in non-GAAP diluted EPS to $2.55. The company is also raising its fiscal year 2026 non-GAAP EPS guidance to a range of $9.65 to $9.85 and adjusted free cash flow outlook to $3.0 to $3.5 billion.

The Pharmaceutical and Specialty Solutions segment contributed significantly to this growth, with revenues climbing 23% to $59.2 billion, driven by brand and specialty pharmaceutical sales. The Global Medical Products and Distribution segment experienced a 2% revenue increase to $3.2 billion. Cardinal Health also anticipates completing the acquisition of Solaris Health in early November, which is expected to further enhance its operational capabilities. The company has initiated a $375 million accelerated share repurchase program in the first quarter, signaling a commitment to returning value to shareholders.

Oct 30, 2025 06:52:52

Cardinal Health Secures $1 Billion Credit Agreement for Operations

Cardinal Health, Inc. has entered into a new 364-Day Credit Agreement with Bank of America, providing access to $1.0 billion in revolving credit until October 6, 2026. This agreement follows the expiration of a previous credit agreement from October 2024 and allows for the conversion of outstanding loans into non-revolving term loans under specific conditions. The facility is intended for general corporate purposes and supports the company's commercial paper program.

The Credit Agreement includes a financial covenant requiring Cardinal Health to maintain a Consolidated Net Leverage Ratio of no greater than 3.75 to 1.00 at the end of each fiscal quarter. It also outlines customary representations, affirmative and negative covenants, and events of default. Financial institutions involved may provide additional services to the company, for which Cardinal Health pays customary fees.

Oct 10, 2025 06:33:04

Cardinal Health Extends Receivables Purchase Agreement to 2028

Cardinal Health has entered into an amendment to its receivables purchase agreement, extending the term of the facility until September 28, 2028. This agreement involves several financial institutions, including Wells Fargo Bank, Liberty Street Funding, and Bank of America, which have previously provided various banking services to the company.

The amendment is part of a broader arrangement that includes a $2.0 billion revolving credit facility, with multiple banks acting as members of the lending syndicate. The involvement of these financial institutions suggests ongoing support for Cardinal Health's financing needs, which may influence investor confidence.

Oct 03, 2025 06:25:39

Cardinal Health Raises $1 Billion Through Public Notes Offering

Cardinal Health, Inc. completed a public offering totaling $1 billion, comprising $600 million in 4.500% Notes due 2030 and $400 million in 5.150% Notes due 2035. The proceeds from this offering will primarily be used to fund the acquisition of Solaris Health, as well as cover associated fees and expenses. Until the proceeds are allocated for the acquisition, the company may use them for general corporate purposes.

The Notes are subject to a special mandatory redemption if the acquisition is not completed by August 12, 2026, or if the company decides not to pursue the acquisition. In such cases, the Notes will be redeemed at 101% of their principal amount, plus any accrued interest. The offering was conducted under an effective registration statement previously filed with the SEC, and the legal opinions regarding the issuance of the Notes were provided by the company’s counsel.

Aug 27, 2025 17:02:44

Cardinal Health Issues $1 Billion in New Notes Offering

Cardinal Health, Inc. has entered into an underwriting agreement to sell $600 million of 4.500% Notes due 2030 and $400 million of 5.150% Notes due 2035. This offering is conducted under the company's effective registration statement filed with the Securities and Exchange Commission.

The underwriting agreement involves Goldman Sachs & Co. LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC as representatives of the underwriters. A complete copy of the Underwriting Agreement is available as an exhibit in the current report.

Aug 14, 2025 17:06:21

Cardinal Health Announces Fiscal 2025 Results and Acquisition Plans

Cardinal Health reported fourth quarter fiscal year 2025 revenues of $60.2 billion, which remained relatively flat compared to the same quarter in fiscal year 2024. Excluding the impact of a previously communicated customer contract expiration, revenue increased by 21%. The company reported GAAP operating earnings of $428 million, with a GAAP diluted earnings per share (EPS) of $1.00. Non-GAAP operating earnings rose 19% to $719 million, and non-GAAP diluted EPS increased 13% to $2.08. For the entire fiscal year 2025, revenues totaled $222.6 billion, marking a 2% decrease from the previous year, but an 18% increase when excluding the contract expiration effect.

Additionally, Cardinal Health announced the acquisition of Solaris Health, a leading urology management services organization, as part of its growth strategy. The company raised its non-GAAP EPS guidance for fiscal year 2026 to a range of $9.30 to $9.50, reflecting anticipated growth driven by contributions from its Pharmaceutical and Specialty Solutions segment. Cardinal Health's fiscal year 2025 adjusted free cash flow was reported at $2.5 billion, indicating strong cash generation capabilities.

Aug 12, 2025 06:59:12

Cardinal Health Raises EPS Guidance and Long-Term Growth Targets

Cardinal Health has updated its fiscal year 2025 guidance, raising the non-GAAP diluted EPS to a range of $8.15 to $8.20, reflecting a 9% growth at the midpoint. The company also provided preliminary guidance for fiscal year 2026, estimating non-GAAP diluted EPS between $9.10 and $9.30, which indicates a growth of 13% at the midpoint. Additionally, Cardinal Health has raised its long-term targets for profit growth in its Pharmaceutical and Specialty Solutions segment to 5% to 7% and for Other profit to approximately 10% normalized growth.

The company expects to generate at least $10 billion in total adjusted free cash flow over the next three years and has increased its baseline share repurchase plans to at least $750 million per year. Cardinal Health continues to focus on strategic priorities, including investments in its Pharmaceutical Distribution and Specialty Solutions, and plans to invest at least $600 million annually in capital expenditures to support organic growth across its businesses.

Jun 12, 2025 06:47:01

Cardinal Health Reports Flat Revenue, Raises EPS Guidance for 2025

Cardinal Health announced its third quarter fiscal year 2025 results, reporting revenue of $54.9 billion, which remained flat compared to the same quarter in the previous year. Excluding the impact of a customer contract expiration, revenue increased by 19%. The company's GAAP operating earnings reached $730 million, and GAAP diluted earnings per share (EPS) were $2.10. Non-GAAP operating earnings increased by 21% to $807 million, with non-GAAP diluted EPS rising by 13% to $2.35, reflecting segment profit growth across all operating segments.

The company has raised and narrowed its fiscal year 2025 non-GAAP EPS guidance to a range of $8.05 to $8.15, up from the previous range of $7.85 to $8.00. This updated guidance includes an increased outlook for segment profit growth in both the Pharmaceutical and Specialty Solutions and Other segments. Additionally, Cardinal Health completed a $375 million accelerated share repurchase program and announced its expansion into the urology specialty therapeutic area through GI Alliance. The company remains focused on operational execution and value creation.

May 01, 2025 06:49:54

Cardinal Health Appoints Two New Directors to Board

Cardinal Health has elected Robert Musslewhite and Sudhakar Ramakrishna as independent directors, effective March 7, 2025. Musslewhite brings over 20 years of leadership experience in healthcare analytics and technology, having served as CEO for two publicly traded companies. He will be part of the Audit and Human Resources and Compensation Committees. Ramakrishna, with extensive experience in technology leadership, will serve on the Audit and Risk Oversight Committees, contributing his expertise in cybersecurity and crisis management to the board.

The appointments were welcomed by Cardinal Health's Chairman Gregory Kenny and CEO Jason Hollar, who emphasized the value of their backgrounds in technology and business strategy. Both directors have held significant positions in various companies, which aligns with Cardinal Health's focus on navigating complex business environments. Their addition to the board is seen as a move to enhance the company's capabilities in technology-oriented healthcare solutions.

Mar 10, 2025 06:53:45